Merck & Co.'s Tulisokibart Shows Promising Trial Results

Merck & Co., Inc. (ISIN US58933Y1055) announced positive phase 2b trial results for its treatment, tulisokibart, on September 30, 2026.

The high-dose group achieved a 72.00 percent HiSCR50 response rate at week 16, exceeding the primary endpoint. The medium-dose group reached 64.00 percent, giving Merck two successful dose levels.

This milestone comes with a higher price target from Scotiabank, which increased its target to USD 180.00 from USD 155.00 on September 29, 2026.